Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety of CHF5993 (Trimbow) in COPD
NCT01584505Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2012
- Primary completion
- Sep 2012
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in average 24-hour heart rate at Day 14. Started Apr 2012; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01584505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01584505.